Cannabinoids & ALS: A UK Perspective on Support

Amyotrophic Lateral Sclerosis (ALS), often known as Lou Gehrig’s Disease, is a devastating neurodegenerative condition that progressively affects nerve cells in the brain and spinal cord, leading to loss of muscle control. As individuals seek ways to manage the challenging symptoms of this complex disorder, there's growing interest in alternative and complementary therapies. Among these, cannabinoids, compounds derived from the cannabis plant, are emerging as a subject of significant discussion and research due to their wide range of potential therapeutic properties.

Understanding Amyotrophic Lateral Sclerosis (ALS)

ALS is a relentless disease characterised by the gradual breakdown and death of motor neurons – the specialised nerve cells responsible for transmitting messages from the brain to the muscles. As these vital neurons are destroyed, the muscles they control weaken and waste away, leading to a progressive loss of voluntary movement. Patients eventually lose the ability to walk, speak, swallow, and even breathe unassisted, as the disease ultimately becomes fatal when respiratory muscles fail.

Symptoms of ALS

The onset of ALS can be subtle, with symptoms often starting gradually and worsening over time. Common indicators include:

• Tripping or difficulty walking
• Dropping things or problems with hand dexterity
• Slurred speech (dysarthria)
• Difficulty swallowing (dysphagia)
• Unintended weight loss due to muscle atrophy
• Decreased muscle tone
• Shortness of breath, especially during exertion
• Changes in reflexes (increased or decreased)
• Uncontrollable periods of laughing or crying (emotional lability)
• General feeling of weakness and fatigue
• Muscle cramping or twitching (fasciculations)
• Muscle stiffness or rigidity (spasticity)
• Poor concentration and mood changes

Types of ALS

ALS manifests in two primary forms:

1. Sporadic ALS: This is the most common form, accounting for 90% of cases. It can affect anyone, regardless of gender, ethnicity, or age, though it is more prevalent in men, Caucasian individuals, and those over 60 years old, with peak onset typically between 58 to 63 years.
2. Familial ALS: This inherited form accounts for 5% to 10% of cases and often presents at a younger age, with peak onset around 47 to 52 years. It is linked to specific genetic mutations, such as those in the superoxide dismutase-1 (SOD1), TAR-DNA binding protein-43 (TDP-43), FUS (fused in sarcoma), and C9orf72 genes.

Another manifestation is Bulbar ALS, where the motor neurons in the brainstem (corticobulbar region) are affected first. This leads to paralysis of muscles in the face, neck, and head before other body areas, in contrast to limb-onset or respiratory-onset ALS.

What Causes ALS?

The precise cause of ALS remains largely unknown, but research points to a multifactorial aetiology involving a combination of genetic predispositions and environmental factors. Theories for contributing factors include exposure to tobacco or formaldehyde, heavy metals, and specific genetic mutations.

Current Treatments for ALS

Currently, there is no cure for ALS. Available treatments, such as riluzole (a glutamatergic neurotransmission inhibitor) and edaravone (an antioxidant drug), aim to slow disease progression and extend life expectancy by a few months. These medications do not provide symptomatic relief. Alongside pharmacological treatments, patients often undergo physical therapy, occupational therapy, and rehabilitation. Additionally, medications like antidepressants, anxiolytics, and pain relievers are prescribed to manage specific symptoms.

The Science Behind Cannabinoids

The cannabis plant contains over 500 natural compounds, approximately 70 of which are classified as cannabinoids. The most well-known include delta-9-tetrahydrocannabinol (THC), the primary psychoactive component, and cannabidiol (CBD), a non-psychoactive compound that has garnered significant therapeutic interest. Other notable cannabinoids include cannabigerol (CBG), cannabinol (CBN), and cannabichromene (CBC).

How Cannabinoids Interact with the Body

Cannabinoids exert their effects primarily by interacting with the body's endocannabinoid system (ECS). This complex biological system plays a crucial role in regulating a wide range of physiological processes, including mood, pain sensation, appetite, memory, and immune response. The ECS comprises endocannabinoids (naturally produced cannabinoids), enzymes that synthesise and degrade them, and cannabinoid receptors.

The two main cannabinoid receptors are:

• CB1 Receptors: Predominantly found in the brain and central nervous system, influencing memory, mood, pain, and movement.
• CB2 Receptors: Primarily located in cells of the immune system and peripheral organs, playing a role in inflammation and pain.

Beyond these, growing evidence suggests the existence of 'non-CB1' and 'non-CB2' receptors, such as transient receptor potential vanilloid type 1 (TRPV1) and G protein-coupled receptor 55 (GPR55), through which cannabinoids can also exert their effects.

Key Properties of Cannabinoids

Cannabinoids, particularly CBD and THC, possess properties that make them attractive for investigating in neurodegenerative conditions like ALS:

• Anti-inflammatory: They can inhibit the release of pro-inflammatory cytokines, suppressing inflammatory responses in the brain and body.
• Antioxidant: They show potent action in inhibiting oxidative and nitrosative stress, reducing the production of reactive oxygen species (ROS) that contribute to cellular damage.
• Neuroprotective: They may protect nerve cells from damage and degeneration.
• Anti-excitotoxic: They can inhibit excessive glutamate release, a neurotransmitter that, in high levels, can be toxic to neurons.

Cannabinoids as Potential Neuroprotective Agents for ALS

The question of whether cannabinoids truly act as neuroprotective agents in ALS is a central point of research. While the exact pathogenic mechanisms of ALS are still being unravelled, factors like oxidative stress, inflammation, and excitotoxicity are believed to contribute significantly to motor neuron degeneration. Given their demonstrated properties, cannabinoids are a logical area of investigation.

Evidence from Preclinical Studies

Much of the promising evidence for cannabinoids' neuroprotective potential in ALS comes from preclinical studies, primarily using the hSOD1(G93A) transgenic mouse model, which mimics many aspects of human ALS.

• THC's Role: Studies have shown that treatment with delta-9-THC in ALS hSOD(G93A) mice, whether initiated before or after symptom onset, can improve motor impairment and modestly increase survival rates (e.g., by 5%). This effect is thought to be mediated through its anti-glutamatergic and antioxidant activities. Interestingly, THC's antioxidant effect was found to be independent of the CB1 receptor, while its protection against excitotoxicity was CB1-receptor mediated.
• Other Cannabinoids: Cannabinol (CBN), a non-psychoactive cannabinoid, has also been shown to significantly delay disease onset in these mouse models, although it did not affect overall survival. Similarly, the CB1/CB2 receptor agonist WIN 55,212-2 delayed disease progression but did not extend lifespan.
• Endocannabinoid System Modulation: Genetic manipulation that increases the levels of the endocannabinoid anandamide (by ablating the FAAH enzyme) has prevented the appearance of disease signs in mice. Conversely, deleting the CB1 receptor in mice has unexpectedly extended lifespan by 15 days, suggesting that beneficial effects might be mediated by non-CB1 receptors, possibly CB2.
• CB2 Receptor Focus: Research indicates a dramatic and selective upregulation of CB2 receptors in the spinal cords of ALS hSOD(G93A) mice, correlating with disease progression. Daily administration of a selective CB2 agonist (AM-1241) after disease onset in these mice delayed motor impairment and significantly increased survival (by 56%). This suggests that CB2 receptor activation may be a crucial mechanism for neuroprotection by suppressing microglial/macrophage activation.
• Sativex (THC:CBD Combination): A mixture of THC and CBD in an approximately 1:1 ratio, commercially known as Sativex, has also been investigated. In ALS hSOD(G93A) transgenic mice, Sativex was found to be effective in delaying ALS progression during the early stages of the disease and in improving animal survival, although its efficacy decreased in later stages.

Overall, preclinical evidence strongly suggests that cannabinoids can slow ALS progression, extend life expectancy, and reduce disease severity, often through the activation of CB2 receptors, which are involved in reducing neuro-inflammation, excitotoxicity, and oxidative cell damage.

Human Clinical Trials and Limitations

Despite the promising animal data, robust human clinical trials specifically investigating cannabinoids as disease-modifying therapies for ALS progression are unfortunately limited. Most human studies have focused on the alleviation of ALS-related symptoms rather than disease control or prolongation of survival. This remains a significant challenge for future research.

Alleviating ALS Symptoms with Cannabinoids

While definitive evidence for disease modification in humans is still being sought, anecdotal reports and limited studies suggest that cannabinoids can offer symptomatic relief for ALS patients. The primary mechanisms through which CBD and THC are thought to benefit ALS patients are their muscle-relaxing, anti-inflammatory, and analgesic (pain-relieving) qualities.

Pain Relief

Pain is a common and often debilitating symptom for ALS patients, stemming from muscle strain, immobility, spasms, and medical procedures. Cannabis products, including those with CBD and THC, have been studied for chronic pain relief in various conditions. Oral sprays or sublingual forms of combined CBD and THC have shown potential for short-term pain relief. While this may offer an alternative to traditional pain relievers, potential side effects such as dizziness and sleepiness should be considered, especially in older patients.

Muscle Spasticity

Muscle stiffness and tightness, or spasticity, affects about a third of ALS patients. While research directly on ALS spasticity is limited, cannabis-based products have been extensively studied and widely used for spasticity in multiple sclerosis (MS). Nabiximols (Sativex), an oral spray containing both THC and CBD, is approved in many countries for MS spasticity. A clinical trial in ALS patients found that six weeks of nabiximols treatment eased spasticity, and a small German study also reported high satisfaction with a THC/CBD combination for mild to severe muscle spasticity in ALS. These findings suggest potential benefits, but more comparative research is needed.

Bladder Problems

Spasticity can also affect bladder control, leading to urinary problems in ALS. Sativex has shown positive results for urinary issues in MS patients, particularly those with an overactive bladder. However, no specific studies have examined cannabis-based products for urinary symptoms in ALS.

Mental Health Support

Coping with a progressive neurodegenerative disease like ALS can significantly impact mental health. Patients have reported that cannabis products help improve their mental well-being. CBD, being non-psychoactive, is widely used for anxiety, post-traumatic stress disorder, and depression, with some evidence supporting its positive effects. However, it's crucial to acknowledge that cannabis use, especially frequent use, can be linked to disorientation, unpleasant thoughts, anxiety, and paranoia, with a potential risk of developing other mental illnesses, particularly in younger individuals.

Other Potential Benefits

Cannabinoids may also help with other challenging ALS symptoms:

• Insomnia: Promoting better sleep quality.
• Nausea and Vomiting: Reducing discomfort and improving tolerance to food.
• Appetite Stimulation: Particularly THC, which can help combat weight loss and cachexia.
• Saliva Reduction: A survey of ALS patients suggested cannabis may help ease drooling.

Navigating CBD Use for ALS: Practical Advice

While the research is promising but still developing, if you are considering using CBD or cannabis products for ALS, it's vital to do so judiciously and under medical supervision. Here are some key tips:

Choosing the Right Product

• Opt for Full-Spectrum Extracts: Whenever possible, look for full-spectrum CBD products. These contain not only CBD but also other cannabinoids (like trace amounts of THC, CBG, CBN) and terpenes found naturally in the cannabis plant. This combination is believed to create an 'entourage effect,' where the compounds work synergistically to enhance therapeutic benefits.
• Prioritise Quality: Always choose high-quality CBD products from reputable manufacturers. Poor-quality products may contain contaminants (e.g., pesticides, heavy metals, residual solvents) that could introduce new health problems or potentially exacerbate ALS progression. Look for products with third-party lab testing results.

Usage Guidelines

• Consistency is Key: Any potential benefits from CBD for ALS symptoms are likely to take several weeks to develop. Be patient and persistent with your supplementation.
• Use Alongside Other Treatments: ALS is a complex disorder requiring a multifaceted approach. CBD should be considered an adjunct therapy to complement, not replace, your prescribed medical treatments and rehabilitation programmes.
• Consult Your Doctor: This is perhaps the most crucial piece of advice. Before initiating any CBD or cannabis product, speak with your specialist who manages your ALS.

Dosage Recommendations

Given the lack of extensive clinical trials specifically for CBD in ALS, there are no universally defined dosages. However, studies involving CBD for other neurodegenerative disorders often suggest that higher dosages may be required to achieve therapeutic benefits. It is therefore likely that a similar approach would apply to ALS.

• Start Low, Go Slow: Begin with a low dose and gradually increase it. A common recommendation is to add 2mg to 5mg of CBD each day or every few days until symptoms are alleviated.
• Monitor Effects: Pay close attention to how your body responds. For symptoms like insomnia, pain, or muscle tremors, relief might be felt relatively quickly. However, any potential longevity-enhancing effects, as seen in animal models, would take much longer and might not be immediately noticeable.
• Aim for High-Strength (Under Guidance): For chronic conditions like ALS, aiming for a higher strength dose of CBD, taken consistently over the long term, is often recommended for best results. However, this must always be done in consultation with your doctor.

Risks and Legal Considerations

Self-medicating with cannabis carries inherent risks, particularly when using unregulated products or without professional medical guidance. It is essential to be aware of potential adverse reactions and interactions.

Potential Adverse Reactions and Interactions

• Medication Interactions: CBD can interact with certain medications by affecting liver enzymes (specifically the cytochrome P450 system) that metabolise drugs. This can alter the effectiveness or increase the side effects of your existing ALS medications (e.g., riluzole, edaravone) or other drugs like antidepressants, anxiolytics, and pain relievers. Your doctor may need to monitor your liver enzymes regularly if you are on standard ALS treatments.
• Respiratory Issues: Smoking or vaping cannabis is generally not recommended for people with ALS. Individuals with ALS may already experience breathing difficulties, which could be worsened by inhaling smoke or vapour, leading to lung irritation, infections, bronchitis, increased mucus, and exposure to harmful chemicals.
• Psychiatric Effects: While CBD is non-psychoactive, products containing THC can cause disorientation, anxiety, paranoia, and, in rare cases, psychosis. Long-term use of cannabis may also be linked to problems with memory and concentration.
• Cardiovascular Problems: Cannabis use has been linked to abnormal heart rhythms in some individuals.

Regulation and Legality

The regulation of CBD and cannabis products varies significantly across different countries. In the UK, CBD products are legal if they contain less than 0.2% THC and are sold as a novel food or supplement. However, the market can still be inconsistent in terms of product quality and accurate labelling. Always ensure you purchase from reputable sources that provide third-party lab testing results to verify purity and cannabinoid content.

Comparative Table: CBD vs. THC for ALS Support

Understanding the distinct properties of CBD and THC can help in discussing treatment options with your healthcare provider.

Frequently Asked Questions (FAQs)

Q: Are cannabinoids truly neuroprotective for ALS?

A: Preclinical animal studies, particularly those involving THC and compounds targeting CB2 receptors, have shown promising neuroprotective effects by reducing inflammation, oxidative stress, and excitotoxicity in ALS models. However, human clinical trials have primarily focused on symptom management, and conclusive evidence for neuroprotection or slowing disease progression in humans is still lacking.

Q: Can cannabinoids prolong the survival time for ALS patients?

A: In certain animal models of ALS (e.g., SOD1-G93A mice), cannabinoids have demonstrated a modest increase in survival time. For instance, some studies reported a survival increase of a few days. However, there is currently no conclusive evidence from human clinical trials to confirm this effect or quantify it in patients.

Q: Is it safe to smoke cannabis if I have ALS?

A: Smoking or vaping cannabis is generally not recommended for individuals with ALS. Given the potential for existing respiratory difficulties, inhaling smoke or vapour can irritate the lungs, worsen breathing problems, and expose you to harmful chemicals. Oral forms like oils, tinctures, or edibles are typically preferred.

Q: What's the best way to take CBD for ALS symptoms?

A: For ALS symptoms, oral forms such as CBD oils, tinctures, capsules, or edibles are generally preferred as they avoid respiratory irritation. It is recommended to choose high-quality, full-spectrum CBD products to potentially benefit from the 'entourage effect' of other cannabinoids and terpenes. Always discuss the most appropriate form and dosage with your doctor.

In conclusion, the potential of cannabinoids, particularly CBD and THC, as supportive therapies for Amyotrophic Lateral Sclerosis is a rapidly evolving area of research. While preclinical studies offer encouraging insights into their neuroprotective capabilities and ability to prolong survival in animal models, human clinical trials have predominantly focused on alleviating the burdensome symptoms of ALS, such as pain, spasticity, and anxiety. There is currently no definitive cure for ALS, and cannabinoids should not be viewed as a standalone treatment. Instead, they represent a promising avenue for adjunct therapy, offering a potential pathway to improved comfort and quality of life for patients. As with any new treatment, it is paramount to engage in open and thorough discussions with your healthcare provider before incorporating cannabinoids into your regimen, ensuring safe and informed choices that complement your existing medical care. Continued rigorous research is essential to fully understand and harness the therapeutic potential of these compounds for ALS.

If you want to read more articles similar to Cannabinoids & ALS: A UK Perspective on Support, you can visit the Automotive category.